IP Library Granted Patent US 7,807,203
Granted Patent B2
US 7,807,203 · App. 12/564,174 · Granted Oct 5, 2010

Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,807,203
App. No.
12/564,174
Granted
Oct 5, 2010
Kind
B2
Abstract

The invention provides hops ( Humulus lupulus ) extracts or derivatives thereof for use in treating a patient prophylactically and/or therapeutically for ulcerogenic-type disorders of the stomach and/or intestines. The ulcerogenic disorders can be of the type chemically induced, environmentally-induced, infection-induced, and/or stress-induced. The invention also provides a pharmaceutical composition comprising an active amount of hops extracts or derivatives thereof, in combination with an analgesic compound and/or an anti-inflammatory compound. The invention further provides for use of hops extracts or derivatives thereof, significantly reducing and/or therapeutically treating ulcerogenic-type disorders of the stomach and/or intestines.

Claims (5)

1. A method of reducing gastric toxicity associated with a administration of a non-steroidal anti-inflammatory compound in a mammal, comprising administering to the mammal being treated with the non-steroidal anti-inflammatory compound a daily dose of about 0.5 to about 10,000 mg per day of a compound selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-isoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-isoadhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-isoadhumulone.

2. The method of claim 1 , wherein the compound is derived from hops.

3. The method of claim 1 , wherein the compound is administered at a daily dose of about 50 to about 7,500 mg per day.

4. The method of claim 1 , wherein the compound is administered with a pharmaceutically acceptable carrier.

5. The method of claim 1 , wherein the compound is administered orally, topically, parenterally, or rectally.

Assignments (2)
SECURITY AGREEMENT Recorded Sep 8, 2010
From: META PROTEOMICS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 024957/0394 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2009
From: BABISH, JOHN G.; TRIPP, MATTHEW L.; BLAND, JEFFREY S.; HOWELL, TERRENCE; DARLAND, GARY K.; LERMAN, ROBERT H.; LUKACZER, DANIEL O.
To: METAPROTEOMICS, LLC
Reel/Frame 023264/0936 →